Physician profile
Diana Wright
NPI 1295971661
$2,674.04
in general payments reported to CMS, 2019-2025
21 companies · $825 in 2025
The $825 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $442 · 2023: $426 · 2024: $684 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,934.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $826.00 | 2021-2025 | |
| Novo Nordisk INC | $471.56 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $273.22 | 2023-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $149.60 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $132.59 | 2021-2024 | Freestyle Libre 3 |
| Journey Medical Corporation | $125.00 | 2021 | |
| Lilly USA, LLC | $116.48 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $104.25 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.21 | 2021-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $89.72 | 2022-2025 | |
| Dexcom, INC. | $49.26 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $39.87 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $36.01 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $27.99 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $22.71 | 2025 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.50 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.49 | 2025 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $22.05 | 2025 | Fanapt |
| Biohaven Pharmaceuticals, INC. | $13.57 | 2021 | |
| Sanofi Pasteur INC. | $13.33 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.